BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Confe

BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue in

RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Se

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains

Drug pricing is back on the front page, and healthcare investors have barely flinched. The White Hou

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nas

Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, In

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared

BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchis

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in B

BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to p

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted ea

ADAR1 Capital Management LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) dur

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have received a consensus

Bank of America Corp DE boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 231.6%

Assenagon Asset Management S.A. boosted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical re

Investors need to pay close attention to BCRX stock based on the movements in the options market lat

BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based r

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals NASDAQ: BCRX reported second-quarter results marked by growth in ORLADEYO r

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zack

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Neutral and announc

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and

HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today ann

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven ab

Studies highlight the significant healthcare and quality-of-life burden associated with hereditary a

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and rec

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperfo

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.14 per share which beat the analyst

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibar

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.06 per share which beat the analyst

BioCryst Pharma (NASDAQ:BCRX) reported quarterly sales of $163.284 million which beat the analyst co

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abs